

University of Dayton

eCommons

---

Mechanical and Aerospace Engineering  
Graduate Student Publications

Department of Mechanical and Aerospace  
Engineering

---

7-1-2023

## Energy Efficiency and Carbon Footprint Reduction in Pharmaceutical Research & Development Facilities

Vibhu Sharma

*University of Dayton*, sharmav9@icloud.com

Abhimanyu Singh

*Defence Institute of Advanced Technology*

Follow this and additional works at: [https://ecommons.udayton.edu/mee\\_grad\\_pub](https://ecommons.udayton.edu/mee_grad_pub)

---

### eCommons Citation

Sharma, Vibhu and Singh, Abhimanyu, "Energy Efficiency and Carbon Footprint Reduction in Pharmaceutical Research & Development Facilities" (2023). *Mechanical and Aerospace Engineering Graduate Student Publications*. 18.

[https://ecommons.udayton.edu/mee\\_grad\\_pub/18](https://ecommons.udayton.edu/mee_grad_pub/18)

This Article is brought to you for free and open access by the Department of Mechanical and Aerospace Engineering at eCommons. It has been accepted for inclusion in Mechanical and Aerospace Engineering Graduate Student Publications by an authorized administrator of eCommons. For more information, please contact [mschlengen1@udayton.edu](mailto:mschlengen1@udayton.edu), [ecommons@udayton.edu](mailto:ecommons@udayton.edu).

# Energy Efficiency and Carbon Footprint Reduction in Pharmaceutical Research & Development Facilities

Vibhu Sharma<sup>1</sup>, Abhimanyu Singh<sup>2</sup>

<sup>1</sup>Energy Engineer, Energy Group  
Grumman/Butkus Associates  
Evanston IL, USA  
sharmav9[at]icloud.com

<sup>2</sup>JRF (Junior Research Fellow)  
Defence Institute of Advanced Technology (DIAT),  
Pune, India  
abhimanyus1997[at]gmail.com

**Abstract:** *The pharmaceutical industry faces significant challenges in reducing energy consumption and carbon footprint due to its energy-intensive operations, particularly in Research & Development (R&D) facilities. This paper presents a case study of a comprehensive energy assessment conducted at a leading pharmaceutical R&D facility. The assessment aimed to identify energy use reduction opportunities to align with the broader corporate strategy of carbon footprint reduction. This study details the methodology, findings, and strategic implementation plan for enhancing energy efficiency and sustainability in pharmaceutical R&D operations.*

**Keywords:** Pharmaceutical Research & Development, Energy Efficiency, Carbon Footprint Reduction, Sustainability in Pharmaceutical Industry, Energy Management Strategies, Renewable Energy Sources, Energy Consumption Analysis, Heat Pump Technology, Environmental Impact Reduction

## 1. Introduction

The pharmaceutical industry's imperative to align with global sustainability standards has never been more critical, especially within the Research & Development (R&D) sector. The R&D facilities, recognized for their significant contributions to medical advancements, are also among the most energy-intensive operations in the industrial landscape. This case study focuses on a comprehensive energy assessment of a leading pharmaceutical R&D facility located in North America. The facility under study stands as a representative model of the broader challenges and opportunities present across the sector, particularly in regions with similar operational scales and sustainability ambitions.[1][2]

In North America, the pharmaceutical sector is navigating a complex matrix of regulatory, environmental, and social pressures to innovate sustainably. The subject facility, with its diverse and energy-intensive operations ranging from laboratory activities to data processing and environmental control systems, embodies the typical energy usage patterns and sustainability challenges faced by the industry. The energy assessment conducted at this facility was based on data collected throughout the calendar year 2022, offering a detailed snapshot of its energy consumption profile and paving the way for targeted interventions.[2]

The calendar year 2022 served as a critical baseline for understanding the facility's energy dynamics, with a particular emphasis on the consumption of electricity and natural gas. These two energy sources are pivotal in supporting the high-precision environments required for

pharmaceutical research, including HVAC systems to maintain strict temperature and humidity levels, lighting for laboratories and office spaces, and power for specialized research equipment. The assessment's timing allows for an accurate reflection of the facility's operational energy needs, seasonal variations, and potential inefficiencies that could be addressed through targeted energy management strategies.[1]

By situating the assessment within the North American context and the specific timeframe of 2022, this study not only provides insights into the energy usage patterns of the facility but also aligns with broader trends in the pharmaceutical industry's journey towards sustainability. The region's unique energy market dynamics, regulatory environment, and sustainability standards contribute to shaping the energy management strategies that facilities like the one under study must navigate. This regional and temporal specificity enhances the relevance and applicability of the findings and recommendations derived from the energy assessment.[3]

Therefore, this paper aims to dissect the complexities of managing energy consumption in a highly specialized and regulated environment. Through the lens of the North American pharmaceutical R&D facility's experience in 2022, the study underscores the challenges of sustaining energy-intensive operations while pursuing ambitious carbon footprint reduction goals. It sets the stage for a strategic discussion on implementing energy efficiency improvements and sustainability practices, offering a blueprint for similar facilities striving to balance operational excellence with environmental stewardship.

Volume 12 Issue 7, July 2023

[www.ijsr.net](http://www.ijsr.net)

Licensed Under Creative Commons Attribution CC BY

## 2. Methodology

The methodology employed in the energy assessment of the pharmaceutical R&D facility was rigorously aligned with the ISO 50002 standard, which outlines the processes and principles for conducting energy audits. This standard is specifically designed to guide organizations in understanding their energy usage, identifying areas for significant energy efficiency improvement, and establishing a robust basis for implementing energy management strategies. By strictly adhering to ISO 50002, the methodology focused on a detailed examination of the facility's energy consumption, with a particular emphasis on technical HVAC (Heating, Ventilation, and Air Conditioning) systems, recognizing their critical role in energy usage within pharmaceutical R&D operations.[4]

### a. ISO 50002: Energy Audits

ISO 50002 provides a structured framework for energy audits, including prerequisites for conducting an audit, the audit process itself, and the reporting of findings. The standard emphasizes a systematic, comprehensive approach to data collection, analysis, and reporting, ensuring that the audit identifies actionable energy-saving opportunities.[5]

### b. Data Collection and Analysis

Following ISO 50002, the energy audit began with an extensive data collection phase, focusing on the facility's energy consumption data for the calendar year 2022. This phase targeted electricity and natural gas usage, with special attention to HVAC systems, given their significant energy draw. Technical data on HVAC operations, including system specifications, operating hours, energy consumption metrics, and maintenance practices, were collected. This information provided insights into the efficiency of HVAC systems and identified potential areas for energy performance improvement.[1]

To understand the HVAC systems' energy consumption patterns, the audit team analyzed:

**System Design and Configuration:** Evaluating the appropriateness of HVAC system designs relative to the facility's specific needs, including zone layouts, system capacity, and control strategies.

**Operational Efficiency:** Assessing the operational parameters, such as temperature set points, ventilation rates, and the use of economizer cycles, to identify inefficiencies.

**Maintenance Practices:** Reviewing maintenance logs and practices to determine if poor maintenance could be leading to increased energy consumption.

**Energy Management Controls:** Examining the use of advanced energy management systems (EMS) for HVAC control, including the integration of sensors, programmable thermostats, and automation systems to optimize energy use.

### c. Site Visits

As stipulated by ISO 50002, site visits were a crucial component of the audit. These visits allowed the audit team to inspect HVAC equipment firsthand, verify operational data, and identify discrepancies between reported practices and actual operations. During these visits, the team also assessed the physical condition of HVAC components, such as ductwork, filters, and motors, to identify any issues that could impede system efficiency.[6][1]

### d. Identification of Energy Savings Opportunities

Leveraging the technical data collected and observations made during site visits, the audit team identified several energy savings opportunities specific to HVAC systems. These opportunities ranged from simple behavioral changes, such as adjusting temperature set points, to more complex interventions, such as upgrading to high-efficiency equipment or retrofitting existing systems with advanced control technologies.[1]

### e. Reporting and Recommendations

The final step in the ISO 50002-aligned methodology was the development of a comprehensive energy audit report. This report detailed the findings from the HVAC system analysis and presented a prioritized list of energy-saving opportunities, complete with technical specifications, estimated energy savings, implementation costs, and projected payback periods. The report served as a roadmap for the facility to enhance its HVAC energy efficiency and contribute to the broader goals of reducing energy consumption and carbon footprint.

By meticulously following the ISO 50002 standard and focusing on the technical intricacies of HVAC systems, the energy audit provided a clear, actionable plan for improving energy efficiency in the pharmaceutical R&D facility. This methodological approach ensured that the recommendations were not only technically sound but also aligned with the facility's operational needs and sustainability objectives.[7][8][4]

## 3. Findings

The findings from the energy audit, conducted in accordance with ISO 50002, unveiled a complex energy consumption landscape at the pharmaceutical R&D facility, with HVAC systems emerging as a significant energy user. This in-depth analysis illuminated the nuanced interplay between various subsystems of HVAC operations and their collective impact on the facility's overall energy efficiency. Through meticulous examination of HVAC configurations, operational practices, and maintenance schedules, the audit identified several areas where energy efficiency was compromised due to outdated technology, inefficient design, or suboptimal operational practices.

One notable finding was the revelation of inefficiencies in the cooling and heating processes integral to maintaining

the facility's stringent environmental conditions. Specifically, the audit uncovered that the facility's reliance on older, less efficient cooling systems resulted in excessive electricity consumption during warmer months, while heating systems were found to be overutilized during colder periods, primarily due to poor insulation and air infiltration. This scenario was further exacerbated by a lack of advanced controls or automation systems, leading to continuous operation of HVAC systems regardless of actual space occupancy or environmental needs. The energy audit also highlighted the absence of regular, comprehensive maintenance, contributing to degraded system performance and increased energy consumption over time.

Moreover, the audit identified significant opportunities for energy savings through the implementation of modern HVAC technologies, including high-efficiency heating and cooling units, variable frequency drives (VFDs) for fan and pump motors, and smart thermostatic controls. These technologies not only promised to enhance the operational efficiency of the HVAC systems but also offered the potential for substantial energy savings by aligning system operation more closely with real-time environmental and occupancy conditions. Additionally, the findings underscored the value of adopting a more proactive maintenance schedule, which could prevent energy wastage due to equipment malfunctions or inefficiencies, further contributing to the facility's energy optimization efforts.

These findings laid the groundwork for developing targeted strategies to address the identified inefficiencies, positioning the pharmaceutical R&D facility on a path towards achieving its energy reduction and sustainability goals. By focusing on the critical areas identified in the audit, the facility could undertake specific, impactful actions to improve its energy performance, ultimately reducing its operational costs and environmental footprint.

The assessment revealed the facility's annual energy consumption patterns, highlighting a significant reliance on natural gas and electricity. Through detailed analysis, major energy users were identified, including HVAC systems, chilled water generation, and production equipment. A critical insight was the disparity in cost-effectiveness between electricity and natural gas, despite the latter's higher volume usage.




Figure 1: Major Energy Users

#### a. Energy and Carbon Emission Analysis

The study meticulously analyzed the facility's energy mix, consumption patterns, and identified correlations between energy consumption and external weather conditions. It underscored the potential for optimizing energy usage through better understanding and leveraging these correlations.




Figure 2: Electricity vs CDD




Figure 3: Natural Gas vs HDD

#### b. Opportunities for Energy Efficiency and Carbon Reduction

A broad range of energy efficiency and carbon reduction opportunities were identified. These included both low/no cost measures and more significant investments in process optimization and renewable energy sources. Recommendations were made for upgrading lighting systems, optimizing HVAC operations, and adopting high-efficiency equipment.

Table 1: Measure and CO2 emissions reduction

Description	Metric Tonnes CO2 Saved
Phase 1 of recommended metering	894
Phase 2 of recommended metering	894
Install heat pump(s) to generate LPHW on LWreturn to lake	4,907
Decentralise steam generation mitigates steam distribution system losses (R10 RI R13 & Fermentation)	4,359
Heat recovery 100% OA units	699
AHU Setbacks in periods of low occupancy	852
Install heat pumps to generate hot water for HVAC Heating mutually exclusive with APNC001-008	1,649
Install dedicated natural gas fired condensing hot water boilers to generate hot water for HVAC Heating	588
Install dedicated electric hot water boilers to generate hot water for HVAC Heating	2,333
Replace all lighting fixtures with LED lighting	291
Replace all lighting fixtures with LED lighting	102
Install heat pumps to generate hot water for process users & hot glycol for HVAC heating mutually exclusive with	6,712
Install dedicated natural gas fired condensing hot water boilers to generate hot water for process users & hot glycol	239
Install dedicated electric hot water boilers to generate hot water for process users & hot glycol for HVAC heating	930
Implement regeneration for cold WFI use	118
UP generation of WFI	97.3
MVR still to replace WEL still in R7 (steam load reduction)	116.8
Install near pumps to generate hot water for HVAC & not glycol mutually exclusive with APNC001-027	1,359
Install dedicated natural gas fired condensing hot water boilers for HVAC & hot glycol heating (centralise generation)	485
Install dedicated electric hot water boilers for HVAC & hot glycol heating (centralise generation)	1,923
AHU Setbacks in periods of low occupancy	718
Heat recovery from exhaust air in AHU's with 100% FA	1,107
thermal Oxidiser flue gas heat recovery 1600F exit temp observed	2,180
Replace all lighting fixtures with LED lighting	102
Install new VSD Turbo blowers local to each fermentor vessel in place of current LP air distribution & generation	441
Utilise Dissolved Oxygen Control on Low Pressure Air (O2 trim, instrumentation in place) study required of existir	101
Recommission absorption chillers using heat recovery off of new VSD turbo blowers	256
Re-design CHW in Fermentation to run chillers in parallel	1,532
AHU Setbacks in periods of low occupancy	611
Inclai 21MW Solar array	12,200
Biofuel Replacement for remaining fossil fuels	2,756
Total	51,378



#### 4. Proposed Strategy for Implementation

The comprehensive energy audit conducted at the pharmaceutical R&D facility, guided by the principles of ISO 50002, laid the foundation for a multi-phased strategic implementation plan aimed at enhancing energy efficiency and reducing carbon emissions.[9] This plan was meticulously crafted, taking into account the complex requirements and operational intricacies of pharmaceutical R&D operations. It emphasizes a pragmatic approach to energy management, prioritizing interventions based on their potential impact, feasibility, and alignment with the facility's long-term sustainability goals. The proposed strategy encompasses four distinct phases, each building upon the successes of the previous to achieve a holistic improvement in energy performance and environmental stewardship.

##### a. Phase 1: Immediate Energy Management and Efficiency Improvements

The first phase focuses on low-hanging fruits—opportunities for quick gains in energy efficiency with minimal to moderate investment. Key actions include retrofitting existing HVAC systems with advanced controls to enable more precise management of heating, cooling, and ventilation based on real-time occupancy and environmental data. Additionally, upgrading lighting systems to LED technology across the facility can yield significant energy savings. Implementing a comprehensive behavioral change program to encourage energy-conscious practices among staff is also pivotal. This phase aims to establish a strong foundation for energy efficiency, fostering a culture of sustainability while securing immediate financial and environmental benefits.

##### b. Phase 2: Adoption of Renewable Electricity Sources

Transitioning to renewable electricity represents a strategic pivot towards reducing the facility's carbon footprint. This phase involves exploring agreements for the procurement of green electricity through renewable energy certificates (RECs) or direct investment in onsite renewable energy generation, such as solar photovoltaic (PV) panels. Such a shift not only diminishes the facility's reliance on fossil fuels but also aligns with broader corporate sustainability commitments. Evaluating the feasibility and scalability of these renewable options is crucial to ensure they meet the facility's energy demands without compromising operational integrity.

##### c. Phase 3: Electrification of Heating Processes

Building upon the foundation laid in the initial phases, Phase 3 delves into the electrification of heating processes, a move designed to reduce natural gas consumption. Introducing high-efficiency electric heat pumps can significantly improve the heating efficiency by utilizing ambient air or ground-source heat. This phase also explores the potential for waste heat recovery systems to supplement heating needs, thereby

maximizing the utility of every energy unit consumed. Such technological upgrades require careful planning and execution to ensure seamless integration with existing systems without disrupting the critical activities of the R&D facility.

##### d. Phase 4: Integration of Renewable Fuels

The final phase of the implementation strategy marks a bold step towards complete decarbonization of the facility's energy sources. This involves transitioning from fossil-based natural gas to renewable biofuels for any remaining processes that require combustion-based heating. The selection of biofuels must consider the compatibility with existing equipment, availability, and environmental impact. Although this phase might present the most challenging implementation hurdles, including potentially higher fuel costs, it signifies the facility's commitment to achieving net-zero carbon emissions and sets a benchmark for sustainability in the pharmaceutical industry.

Throughout all phases, continuous monitoring, evaluation, and adaptation are essential. Leveraging advanced energy management systems (EMS) to track progress, identify areas for further improvement, and adjust strategies in real-time will be critical to the success of the implementation plan. This phased approach not only charts a course towards significant energy and carbon reductions but also exemplifies a model for sustainable operation that can inspire and guide other pharmaceutical R&D facilities on their path to environmental stewardship and operational excellence.




Figure 4: Carbon Emissions Reduction Waterfall

#### 5. Future Directions and Implications for Sustainable Pharmaceutical Operations

The comprehensive energy assessment and the strategic implementation plan outlined for the pharmaceutical R&D facility have profound future implications, not only for the facility itself but also for the broader pharmaceutical industry and beyond. The transition towards more sustainable operations, as demonstrated by this case study, signals a shift in how the pharmaceutical sector approaches its environmental impact and energy management practices. This shift could potentially catalyze a wave of innovation and transformation across

the industry, leading to the development of new standards for sustainability in pharmaceutical R&D operations.

#### **a. Advancing Sustainability through Innovation**

One original contribution of this case study lies in its potential to spur innovation in energy efficiency technologies and sustainability solutions tailored to the unique needs of pharmaceutical R&D facilities. The implementation of advanced HVAC systems, adoption of renewable energy, and transition to electrification offer fertile ground for developing new technologies and solutions that are not only more energy-efficient but also more effective in maintaining the stringent conditions required for pharmaceutical research. This could lead to the emergence of next-generation HVAC systems with adaptive, AI-driven controls, more efficient heat recovery processes, and breakthroughs in low-carbon heating and cooling technologies.

#### **b. Setting New Benchmarks for Industry Sustainability**

The strategic phased approach to implementing sustainability measures, as detailed in the plan, provides a blueprint for other pharmaceutical facilities and the industry at large. By showcasing a successful model of energy and carbon reduction, this case study encourages the setting of new benchmarks for sustainability within the industry. It challenges other companies to not only meet these benchmarks but also to strive for continuous improvement in their sustainability efforts. This competitive drive can accelerate the adoption of green practices across the industry, leading to substantial reductions in the sector's overall environmental footprint.

#### **c. Fostering a Culture of Environmental Stewardship**

Another significant future implication is the potential to foster a culture of environmental stewardship within the pharmaceutical industry and among its stakeholders. As companies become more transparent about their sustainability efforts and achievements, there is an opportunity to engage employees, customers, investors, and the community in these initiatives. This engagement can build a strong sense of shared responsibility and collective action towards sustainability, amplifying the impact of individual companies' efforts.[10]

#### **d. Influencing Policy and Regulatory Frameworks**

Finally, the outcomes and insights from this case study could influence policy and regulatory frameworks related to energy efficiency and sustainability in the pharmaceutical industry and beyond. By demonstrating what is possible through comprehensive energy assessments and strategic implementation of energy-saving measures, this case study can provide valuable data and justification for more ambitious environmental regulations and policies. It can also serve as a reference for developing industry standards and best practices for

sustainability, potentially shaping future regulations and guidelines.

In conclusion, the original contributions of this case study extend far beyond the immediate energy savings and carbon reductions achieved by the pharmaceutical R&D facility. They lie in its potential to drive innovation, set new industry benchmarks, foster a culture of sustainability, and influence future policy. By charting a course towards more sustainable operations, this case study not only addresses the environmental challenges facing the pharmaceutical industry today but also lays the groundwork for a more sustainable and responsible industry in the future.

## **6. Conclusion**

The comprehensive energy assessment and subsequent strategic implementation plan outlined for the pharmaceutical R&D facility underscore a significant shift towards sustainable operations within the pharmaceutical industry. This case study not only highlights the facility's journey towards achieving substantial energy efficiency and carbon footprint reduction but also sets a precedent for environmental stewardship across the sector. The phased strategy—beginning with immediate efficiency gains and culminating in the integration of renewable energy sources—demonstrates a pragmatic yet ambitious approach to sustainability. It showcases how targeted interventions, grounded in thorough analysis and strategic planning, can lead to significant environmental and economic benefits. This approach not only aligns with global sustainability goals but also offers a blueprint for other pharmaceutical facilities aiming to navigate the complexities of energy management and environmental impact reduction.

Beyond the immediate outcomes of reduced energy consumption and carbon emissions, this case study contributes to a broader dialogue on sustainability within the pharmaceutical industry and beyond. It emphasizes the role of innovation in driving sustainability efforts, from the development of advanced HVAC systems to the adoption of renewable energy technologies. By sharing insights and strategies from this case study, the pharmaceutical industry is encouraged to set new benchmarks for sustainability, fostering a culture of environmental stewardship among stakeholders. Moreover, the successful implementation of the strategic plan detailed here has the potential to influence policy and regulatory frameworks, advocating for more ambitious environmental standards and practices. Ultimately, this case study serves as a testament to the feasibility and value of integrating sustainability into the core operations of pharmaceutical R&D, paving the way for a more sustainable future for the industry.

## **References**

- [1] C. Jiménez-González and M. Overcash, "Energy optimization during early drug development and the relationship with environmental burdens," *Journal of Chemical Technology and Biotechnology*, vol. 75,

- no. 11, pp. 983–990, Jan. 2000, doi: 10.1002/1097-4660(200011)75:11.
- [2] W. Kong, B. Lv, S. Yang, H. Shen, G. Jing, and Z. Zhou, “Case study on environmental safety and sustainability of pharmaceutical production based on life cycle assessment of enrofloxacin,” *Journal of Environmental Chemical Engineering*, vol. 9, no. 4, p. 105734, Aug. 2021, doi: 10.1016/j.jece.2021.105734.
- [3] G. Van Der Vorst, J. Dewulf, W. Aelterman, B. De Witte, and H. Van Langenhove, “A systematic evaluation of the resource consumption of active pharmaceutical ingredient production at three different levels,” *Environmental Science & Technology*, vol. 45, no. 7, pp. 3040–3046, Mar. 2011, doi: 10.1021/es1015907.
- [4] B. Prasetya, D. R. Wahono, A. Dewantoro, W. C. Anggundari, and Yopi, “The role of Energy Management System based on ISO 50001 for Energy-Cost Saving and Reduction of CO<sub>2</sub>-Emission: A review of implementation, benefits, and challenges,” *IOP Conference Series. Earth and Environmental Science (Online)*, vol. 926, no. 1, p. 012077, Nov. 2021, doi: 10.1088/1755-1315/926/1/012077.
- [5] G. Dall’O, S. Ferrari, E. Bruni, and L. Bramonti, “Effective implementation of ISO 50001: A case study on energy management for heating load reduction for a social building stock in Northern Italy,” *Energy and Buildings*, vol. 219, p. 110029, Jul. 2020, doi: 10.1016/j.enbuild.2020.110029.
- [6] N. Thißen, “Mass and energy flow analysis supports process improvement,” *Chemical Engineering & Technology*, vol. 33, no. 4, pp. 573–581, Apr. 2010, doi: 10.1002/ceat.200900459.
- [7] “Energy management,” ISO. <https://policy.iso.org/energy-management.html>.
- [8] G. Dall’O, S. Ferrari, E. Bruni, and L. Bramonti, “Effective implementation of ISO 50001: A case study on energy management for heating load reduction for a social building stock in Northern Italy,” *Energy and Buildings*, vol. 219, p. 110029, Jul. 2020, doi: 10.1016/j.enbuild.2020.110029.
- [9] L. Zhi-dong, Z. Shu-shen, Z. Yun, Z. Yong, and W. Li, “Evaluation of cleaner production audit in pharmaceutical production industry: case study of the pharmaceutical plant in Dalian, P. R. China,” *Clean Technologies and Environmental Policy*, vol. 13, no. 1, pp. 195–206, Apr. 2010, doi: <https://doi.org/10.1007/s10098-010-0288-2>.
- [10] M. Milanesi, A. Runfola, and S. Guercini, “Pharmaceutical industry riding the wave of sustainability: Review and opportunities for future research,” *Journal of Cleaner Production*, vol. 261, p. 121204, Jul. 2020, doi: 10.1016/j.jclepro.2020.121204.